Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPV antigen-loaded dendritic cell-activated cytotoxic T lymphocytes
- Development stage
- Unknown
- Lead developer
- Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HPV antigen-loaded dendritic cell-activated cytotoxic T lymphocytes is an autologous adoptive cell therapy developed by the Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine for the treatment of Human Papillomavirus (HPV) infections. The production process involves isolating peripheral blood mononuclear cells from the patient, differentiating them into dendritic cells (DCs), and loading them with HPV-specific antigens, such as the E6 and E7 oncoproteins. These DCs are then used to prime and expand a population of the patient's own T cells into HPV-specific cytotoxic T lymphocytes (CTLs) ex vivo. Upon re-infusion, these activated CTLs recognize and destroy HPV-infected cells by binding to viral antigens presented on the cell surface, thereby potentially clearing persistent infections and preventing the progression to cervical malignancy.
- Other names
- HPV-DC-CTLHPV-specific cytotoxic T lymphocytes
02
Targets
Human papillomavirus E6 peptide-MHC class I complexpMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on HPV antigen-loaded dendritic cell-activated cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPV antigen-loaded dendritic cell-activated cytotoxic T lymphocytes.